the american depositary receipts of orphazyme as traded 18 lower in thursdays postmarket session after the biopharmaceutical company said its board decided to file a petition for an incourt restructuring orphazyme said it plans to delist its adrs from the nasdaq stock exchange and reduce its workforce by about 50 at 448 pm et the companys adrs were down 18 at 103 each they finished the days regulartrading session with a 59 gain closing at 126 each the adrs touched a 52week low of 104 on monday in february the committee for medicinal products for human use of the european medicines agency indicated it wasnt likely to approve orphazymes marketing application for arimoclomol to treat niemannpick disease type c earlier in the year the us food and drug administration also refused to approve arimoclomal the companys primary drug candidate